Blueberries Medical Reports 2022 Q2 Financial Results and Provides Corporate and Operations Update
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reports significant growth in Q2 2022, doubling revenues to $39,826, driven by extraction services. The shift towards extraction services and successful exports to Argentina support their strategic pivot. The company has established a partnership for GACP CUMSC certified CBD and THC strains and is exploring new markets with innovative water-soluble products. However, operational costs surged, leading to a net loss of $511,717, raising concerns about expense management despite revenue growth.
- Revenue for Q2 2022 increased by 169% year-over-year.
- Successful expansion into the extraction services sector.
- The company is strategically focused on reducing non-essential costs.
- Net loss of $511,717 for Q2 2022, highlighting financial strain.
- Operating expenses surged by 113% compared to the previous year.
TORONTO, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA), the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or "Blueberries"), is pleased to report its financial results for the quarter ended on June 30, 2022. Today, Blueberries has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All amounts are expressed in Canadian dollars, unless otherwise noted.
Blueberries Medical Corp. continues to deploy its strategy by focusing on multiple key revenue-generating activities while reducing non-essential administrative cost, capital and operational expenditures. Additionally, individuals with proven track record in Cannabis / Pharma industries have joined the management team to cover key roles in the organization, primarily in Sales, Quality, Finance, and I+D.
Financial Highlights
All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
During the first 6 months of 2022, the Company has doubled its revenues from its comparative period in 2021; the Company has pivoted its core business from cultivation to the extraction services, and identified a unique niche in export market of isolated products to the Latin America countries. To date, the Company has been successful in exporting isolated products to Argentina. “Accordingly, in aligning with the Company’s strategy, the Company has begun to expand its commercial revenues, adding more final products and services to others cannabis companies in Colombia and Latin America (Latam),” said Facundo Garreton, Chief Executive Officer and Chairman of Blueberries Medical Corp.
Jose Maria Forero, President of Latin America Operations, also expressed, “We continue to focus our efforts guided by the Company’s three fundamental pillars: Operate with Excellence, Connect with Demand, and Differentiate while ensuring our long-term success. The Company is currently in search of a warehouse in Bogota or the suburbs to house the new production equipment, which will allow the Company’s to expand the capability of our facilities to ensure access to GACP CUMSC extraction services both for THC and CBD strains with a minimum CAPEX allocation.”
Jose Maria Forero also added, “To ensure immediate access to premium GACP CUMCS certified CBD and THC flower both for extraction and dry flower exportation purposes, the Company has cultivated an alliance with one of the largest cultivators, with CBD predominant genetic resources, in Colombia."
Business Highlights
The success and work accomplished during Q2 in Argentina has served as the basis for entering the other Latin America market and the Company, being in a second stage of commercial development, is offering more portfolio products such as CBG and CBN isolates. Those products were delivered to four different Cosmetic laboratories as well as one pharmaceutical leading company under commercial arrangement and samples were delivered to, at least, twenty laboratories of food, cosmetic and pharmaceutical sectors.
The poor cannabinoids solubility in water is one of the most challenging conditions and hindrances to penetrate new markets and increase consumption moments. Faced with this challenge, the Company is pleased to announce the launch of the long-awaited water-soluble development with functionality superior to what is currently on the market. The Company has put considerable efforts and investment to improve the technology performance along every single horizon; less turbidity, increased stability since the novel product developed is in solid state and disruptive functional ingredients to yield almost neutral flavor specialty.
BBM has developed different CBD-predominant and THC-predominant formulations, designed in a functional way to attend to different pathologies. With this development, supported by local business partners, BBM intends to penetrate different markets by facilitating the use of its products in patients in need of cannabis-based formulations (not hemp), being the case of THC where its natural source is Delta 9 THC, which exceeds in effectiveness, efficiency, and naturalness the current offer supplied by United States with Delta 8 THC.
New Colombian Regulation
On February 18, 2022, the Colombian government issued the Resolution 227/2022 that improved license holders’ conditions, such as extending from 5 to 10 years the term of the licenses and facilitating the process for applying to THC quotas. This resolution also regulated the use of non-psychoactive cannabis plant and its derivatives in food, beverages, alcoholic beverages, and dietary supplements. In this same direction, on April 1, 2022, the Colombian government issued the Resolution 539/2022 that regulates the Decree 811 of 2021 in all aspects related to the exportation of seeds for sowing, grain, plant component, cannabis plants, cannabis, cannabis derivatives and related products, allowing therefore the exportation of dry flower for medical and scientific purposes.
In anticipation to this regulatory chances, the Company started in mid-2021 specific plans to: a) be ready to export premium grade THC with GACP CUMSC / IMC certification using a third-party cultivator model agreement with one of the largest flower processors in Colombia, (Blueberries already modified their license to be able to export) b) started the development of multiple non-psychoactive high value-added ingredients for Food and Beverages, including specialties for chocolate and a fully translucid CBD water-soluble powder for beverages and other uses.
Blueberries expects that these new opportunities allowed by the updated regulation in Colombia will be rapidly traduced into sales and income for the Company both locally and in development markets during the third quarter of 2022.
Second Quarter 2022 Financial Review
The Company’s current strategic focus is centered in the optimization of the cash position, giving special attention to the continued reduction and control of expenses and to the generation of income through multiple commercial avenues and various product lines and B2B services. The management rigorously ensures that all activities are guided under the three fundamentals pillars of Operate with Excellence, Connect with Demand, and Differentiate.
Results for the first two quarters of 2022 fall within the expectation of the management based on the strategic decision taken for the last quarter of 2021.
The Company has begun to expand its commercial revenues, extending our business model and to provide extraction services to other cannabis companies in Colombia. Together, with the anticipated increased revenue, the Company will focus its spending on CAPEX and EUGMP (European Union Good Manufacturing Practices) certifications.
SUMMARY BALANCE SHEET
| As at June 30, 2022 | As at December 31, 2021 | |||
| Total current assets | $ | 799,817 | $ | 1,563,617 |
| Total assets | 2,556,649 | 3,593,880 | ||
| Total liabilities | 1,976,524 | 2,159,134 | ||
| Total equity | $ | 385,207 | $ | 1,434,746 |
Blueberries’ commercial operations have successfully moved from introductory sales of cuttings of its cultivars to associate growers to effective sales of cannabis derivatives and extracts to customer both in Colombia and Peru. The Company launched a tolling service processing flower and biomass from small and mid-size licensed producers that is also positively impacting revenue results this year.
STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||
| Revenues | $ | 39,826 | $ | 14,785 | $ | 73,541 | $ | 37,905 | ||||
| Cost of sales - product revenues | - | (7,171 | ) | (757 | ) | (8,366 | ) | |||||
| Cost of sales - extraction services | (35,379 | ) | - | (54,419 | ) | - | ||||||
| Direct cost of production - cultivation | (511 | ) | (32,846 | ) | (41,830 | ) | (97,907 | ) | ||||
| Direct cost of production - extraction services | (79,411 | ) | (62,789 | ) | (110,128 | ) | (74,552 | ) | ||||
| Gross profit | $ | (75,475 | ) | $ | (88,021 | ) | $ | (133,593 | ) | $ | (142,920 | ) |
| Expenses | ||||||||||||
| Operating expenses - cultivation | $ | (281 | ) | $ | (17,960 | ) | $ | (22,944 | ) | $ | (53,534 | ) |
| Operating expenses - extraction services | (58,370 | ) | (9,465 | ) | (80,948 | ) | (11,238 | ) | ||||
| General and administrative expenses | (331,097 | ) | 35,692 | (652,170 | ) | (124,261 | ) | |||||
| Depreciation and amortization | (83,867 | ) | (141,191 | ) | (168,557 | ) | (358,217 | ) | ||||
| Finance expense | (77,201 | ) | (64,980 | ) | (152,085 | ) | (127,469 | ) | ||||
| Foreign exchange loss | 22,165 | 8,142 | (4,018 | ) | (27,124 | ) | ||||||
| Total expenses | (528,651 | ) | (189,762 | ) | (1,080,722 | ) | (701,843 | ) | ||||
| Other income (expense) | ||||||||||||
| Gain on disposal of property, plant and equipment | 20,181 | - | 20,181 | - | ||||||||
| Other expense | 72,228 | 8,716 | 26,110 | (14,629 | ) | |||||||
| Total other expenses | 92,409 | 8,716 | 46,291 | (14,629 | ) | |||||||
| Net loss | $ | (511,717 | ) | $ | (269,067 | ) | $ | (1,168,024 | ) | $ | (859,392 | ) |
| Other Comprehensive Loss | ||||||||||||
| Foreign currency translation adjustment | (36,467 | ) | (75,917 | ) | 46,825 | (269,723 | ) | |||||
Comprehensive loss | $ | (548,122 | ) | $ | (344,984 | ) | $ | (1,121,199 | ) | $ | (1,129,115 | ) |
| Net loss per share - basic and diluted | $ | (0.00 | ) | $ | (0.00 | ) | $ | (0.01 | ) | $ | (0.01 | ) |
| Weighted average number of shares outstanding - basic and diluted | 163,810,263 | 142,996,446 | 163,810,263 | 142,996,446 | ||||||||
Revenue
For the three months ended June 30, 2022, the Company generated a total revenue of
| Operating Expenses | Operating expenses | |||||||||||
| Cultivation | Extraction services | Cultivation | Extraction services | |||||||||
| For the three months ended | June 30, 2022 | June 30, 2021 | ||||||||||
| Salary, wages, and benefits | $ | 431 | $ | 7,232 | $ | 15,496 | $ | 6,651 | ||||
| Supplies, spare parts and equipment | 200 | 32,094 | 3,639 | 278 | ||||||||
| License costs | (27 | ) | - | 527 | (2 | ) | ||||||
| Facilities | 1,680 | 2,573 | (2,883 | ) | 915 | |||||||
| Laboratory | - | (2,973 | ) | (3,182 | ) | 427 | ||||||
| Fuel and oil | 36 | 1 | 6,245 | (8 | ) | |||||||
| Transportation | 2 | 992 | (168 | ) | 19 | |||||||
| Utilities | 106 | 416 | 268 | 135 | ||||||||
| Other | (2,147 | ) | 18,035 | (1,982 | ) | 1,050 | ||||||
| $ | 281 | $ | 58,370 | $ | 17,960 | $ | 9,465 | |||||
| Operating Expenses | Operating expenses | |||||||||||
| Cultivation | Extraction services | Cultivation | Extraction services | |||||||||
| For the six months ended | June 30, 2022 | June 30, 2021 | ||||||||||
| Salary, wages, and benefits | $ | 9,429 | $ | 11,192 | $ | 27,477 | $ | 7,165 | ||||
| Supplies, spare parts and equipment | 553 | 33,447 | 5,079 | 340 | ||||||||
| License costs | 16 | - | 570 | - | ||||||||
| Facilities | 4,223 | 4,702 | 1,313 | 1,096 | ||||||||
| Laboratory | 65 | 868 | - | 564 | ||||||||
| Fuel and oil | 51 | 203 | 6,424 | - | ||||||||
| Transportation | 52 | 1,704 | 458 | 46 | ||||||||
| Utilities | 264 | 1,076 | 957 | 165 | ||||||||
| Other | 8,291 | 27,756 | 11,366 | 1,862 | ||||||||
| $ | 22,944 | $ | 80,948 | $ | 53,644 | $ | 11,238 | |||||
Operating Expenses
During the three months ended June 30, 2022, a total of
During the six months ended June 30, 2022, a total of
General and Administrative Expenses
| Three months ended June 30 | Six months ended June 30, | ||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||
| Audit and accounting | $ | 55,275 | $ | 17,500 | $ | 124,568 | $ | 8,683 | |||||
| Consulting | 38,767 | 5,301 | 63,398 | 23,047 | |||||||||
| Director and management fees | - | 43,700 | - | 100,700 | |||||||||
| Filing and transfer agent fees | 23,368 | 7,940 | 34,929 | 32,842 | |||||||||
| General office | 26,166 | 10,171 | 11,216 | 24,979 | |||||||||
| Insurance | 24,561 | 20,568 | 47,425 | 38,183 | |||||||||
| Legal | 7,528 | 4,496 | 8,420 | 4,829 | |||||||||
| Other | 366 | 19,189 | 636 | 22,894 | |||||||||
| Salary, wages, and benefits | 127,447 | 95,731 | 265,245 | 159,511 | |||||||||
| Share based compensation expense (recovery) | 27,182 | (260,265 | ) | 71,660 | (291,425 | ) | |||||||
| Travel | 437 | (23 | ) | 445 | 18 | ||||||||
| Total | $ | 331,097 | $ | (35,692 | ) | $ | 627,942 | $ | 124,261 | ||||
Audit and accounting fees - Audit and accounting fees include cost of audit, accounting and taxation services provided by the Company’s external auditor and other third parties. The increase of
Director and management fees - For the three months ended and six months ended June 30, 2022, the Company incurred $Nil (2021 -
General office - General office expenses include office and equipment rent, utilities, communication, and cleaning services, which are expensed as incurred. For the three months ended June 30, 2022, the Company incurred an increase of
Salary, wages, and benefits-Salary, wages, and benefits include payroll, training, benefits, and severance costs of employees in Colombia. For the three months and six months ended June 30, 2022, the Company incurred an increase of
Share-based compensation expense (recovery) - For the three months and six months ended June 30, 2022, total share-based compensation expenses incurred were
About Blueberries Medical Corp.
Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.
Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:
Jose Forero, President, Latin American Operations
jforero@blueberriesmed.com
Tel: +57 310 345 8808
Guillermo Rodriguez, CFO Blueberries Medical Corp.
grodriguez@blueberriesmed.com
Tel: +54 911 6015 2227
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: commencement of commercial production of CBD-dominant oils and products, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at www.sedar.com.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
FAQ
What were Blueberries Medical Corp's Q2 2022 revenues?
How did Blueberries Medical Corp's financial performance change in 2022?
What is the stock symbol for Blueberries Medical Corp?
What are the recent developments in Blueberries Medical Corp's operations?
What was the net loss for Blueberries Medical Corp in Q2 2022?
